A phase I clinical trial to evaluate the safety and biological activity of HIV-IT (TAF) (HIV-1IIIBenv-transduced, autologous fibroblasts) in asymptomatic HIV-1 infected subjects.
Galpin
J E
JE
Casciato
D A
DA
Richards
S B
SB
D000328:Adult; D002985:Clinical Protocols; D004608:Eligibility Determination; D005260:Female; D005347:Fibroblasts / Q000637:transplantation*; D005500:Follow-Up Studies; D015686:Gene Products, env / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D015497:HIV-1; D006801:Humans; D007117:Immunization, Secondary; D007167:Immunotherapy; D008297:Male; D012307:Risk Factors; D012449:Safety; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D015686:Gene Products, env